These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 32919178)

  • 41. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial.
    Bleker SM; Cohen AT; Büller HR; Agnelli G; Gallus AS; Raskob GE; Weitz JI; Curto M; Sisson M; Middeldorp S
    Thromb Haemost; 2016 Nov; 116(6):1159-1164. PubMed ID: 27583312
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial.
    Cohen AT; Agnelli G; Buller HR; Gallus A; Raskob GE; Sanders P; Thompson J; Weitz JI
    Thromb Haemost; 2019 Mar; 119(3):461-466. PubMed ID: 30650446
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].
    Gómez Arrayas I; Suárez Fernández C; Gómez Cerezo JF; Betegón Nicolás L; de Salas-Cansado M; Rubio-Terrés C
    Rev Esp Salud Publica; 2012 Dec; 86(6):601-12. PubMed ID: 23325135
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative effectiveness and safety of apixaban versus warfarin in patients with venous thromboembolism.
    Dawwas GK; Smith SM; Dietrich E; Lo-Ciganic WH; Park H
    Am J Health Syst Pharm; 2020 Jan; 77(3):188-195. PubMed ID: 31974557
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of outcomes with apixaban use for venous thromboembolism in hospitalized patients with end-stage renal disease receiving renal replacement therapy.
    Chen J; Nguyen S; Ruegger M; Samuel L; Salazar E; Dunne I
    J Thromb Thrombolysis; 2022 Aug; 54(2):260-267. PubMed ID: 35430706
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rivaroxaban or apixaban in fragile patients with acute venous thromboembolism.
    Trujillo-Santos J; Beroiz P; Moustafa F; Alonso A; Morejon E; López-Reyes R; Casado I; Porras JA; Flores K; López-Núñez JJ; Monreal M;
    Thromb Res; 2020 Sep; 193():160-165. PubMed ID: 32623185
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and Effectiveness of Apixaban in Japanese Patients With Venous Thromboembolism in Clinical Practice　- A Post-Marketing Surveillance.
    Yamada N; Mo M; Ohsawa A; Sato M; Umeyama M; Shima D; Nakamura M
    Circ J; 2021 Nov; 85(12):2201-2207. PubMed ID: 33994408
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Case Fatality Rates of Recurrent Thromboembolism and Bleeding in Patients Receiving Direct Oral Anticoagulants for the Initial and Extended Treatment of Venous Thromboembolism: A Systematic Review.
    Gómez-Outes A; Lecumberri R; Suárez-Gea ML; Terleira-Fernández AI; Monreal M; Vargas-Castrillón E
    J Cardiovasc Pharmacol Ther; 2015 Sep; 20(5):490-500. PubMed ID: 25802423
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study.
    Mahé I; Agnelli G; Ay C; Bamias A; Becattini C; Carrier M; Chapelle C; Cohen AT; Girard P; Huisman MV; Klok FA; López-Núñez JJ; Maraveyas A; Mayeur D; Mir O; Monreal M; Righini M; Samama CM; Syrigos K; Szmit S; Torbicki A; Verhamme P; Vicaut E; Wang TF; Meyer G; Laporte S
    Thromb Haemost; 2022 Apr; 122(4):646-656. PubMed ID: 34535037
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism. What do we know so far?
    Voigtlaender M; Langer F
    Hamostaseologie; 2017 Oct; 37(4):241-255. PubMed ID: 28508916
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Apixaban: An Optimal Agent for the Treatment of Cancer-Associated Venous Thromboembolism?
    Grilusová K; Bolek T; Škorňová I; Stančiaková L; Mikušová V; Kubisz P; Galajda P; Staško J; Samoš M; Mokáň M
    Am J Ther; 2021 Sep; 29(2):e212-e218. PubMed ID: 35389573
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice.
    Weycker D; Li X; Wygant GD; Lee T; Hamilton M; Luo X; Vo L; Mardekian J; Pan X; Burns L; Atwood M; Hanau A; Cohen AT
    Thromb Haemost; 2018 Nov; 118(11):1951-1961. PubMed ID: 30357780
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bleeding rates of Veterans taking apixaban or rivaroxaban for atrial fibrillation or venous thromboembolism.
    Howe Z; Naville-Cook C; Cole D
    J Thromb Thrombolysis; 2019 Feb; 47(2):280-286. PubMed ID: 30449001
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Monotherapy Anticoagulation to Expedite Home Treatment of Patients Diagnosed With Venous Thromboembolism in the Emergency Department: A Pragmatic Effectiveness Trial.
    Kline JA; Adler DH; Alanis N; Bledsoe JR; Courtney DM; d'Etienne JP; Diercks DB; Garrett JS; Jones AE; Mackenzie DC; Madsen T; Matuskowitz AJ; Mumma BE; Nordenholz KE; Pagenhardt J; Runyon MS; Stubblefield WB; Willoughby CB
    Circ Cardiovasc Qual Outcomes; 2021 Jul; 14(7):e007600. PubMed ID: 34148351
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin.
    Brekelmans MP; Scheres LJ; Bleker SM; Hutten BA; Timmermans A; Büller HR; Middeldorp S
    Thromb Haemost; 2017 Apr; 117(4):809-815. PubMed ID: 28180233
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hemorrhage risk of direct oral anticoagulants in real-world venous thromboembolism patients.
    Jin MC; Sussman ES; Feng AY; Han SS; Skirboll SL; Berube C; Ratliff JK
    Thromb Res; 2021 Aug; 204():126-133. PubMed ID: 34198049
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New oral anticoagulants in the treatment of acute venous thromboembolism - a systematic review with indirect comparisons.
    Hirschl M; Kundi M
    Vasa; 2014 Sep; 43(5):353-64. PubMed ID: 25147012
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and effectiveness of rivaroxaban and apixaban in patients with venous thromboembolism: a nationwide study.
    Sindet-Pedersen C; Staerk L; Pallisgaard JL; Gerds TA; Berger JS; Torp-Pedersen C; Gislason GH; Olesen JB
    Eur Heart J Cardiovasc Pharmacother; 2018 Oct; 4(4):220-227. PubMed ID: 29945162
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study.
    Stepien K; Nowak K; Zalewski J; Pac A; Undas A
    Vascul Pharmacol; 2019 Sep; 120():106567. PubMed ID: 31158568
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants.
    Ay C; Beyer-Westendorf J; Pabinger I
    Ann Oncol; 2019 Jun; 30(6):897-907. PubMed ID: 30918939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.